Enveric sells cannabis patents to focus on psilocin candidates [Green Market Report]
Friday, February 23, 2024 1 min read
Key Takeaway: Enveric Biosciences is selling its cancer-related patent portfolio to concentrate on developing its lead candidates, EB-003 and EB-002. EB-003 is a neuroplastogen aimed at eliminating hallucinations, while EB-002 is a synthetic prodrug of psilocin. This strategic shift reflects Enveric's commitment to advancing its innovative therapies.
Price reaction · baseline $153 (2024-02-22 close) · hit pre-market · 1 other ENVB headline(s) in the window, move may be shared
day 0 close
+15.3%
day 1
+0.2%
day 3
-2.2%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric is strategically refocusing on promising psilocin candidates.
The sale of the patent portfolio allows for increased investment in lead candidates.
EB-003 and EB-002 represent innovative approaches in neuropharmacology.
Full Press Release Details
Enveric Biosciences (NASDAQ: ENVB) is selling one of its cancer-related patent portfolios for an undisclosed amount. Enveric said it plans to continue to focus and invest in the development of its lead candidates EB-003, a first-in-class neuroplastogen designed to eliminate hallucinations, and EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin.
Full Article >>
Frequently Asked Questions
What is Enveric selling?
Enveric is selling its cancer-related patent portfolio.